MD Anderson is known for providing cancer patients with exceptional care, which includes early access to innovative new treatments through clinical trials. The Institute for Applied Cancer Science (IACS) is a new hybrid model that uniquely combines the drug discovery capabilities of the biopharmaceutical industry and the extensive knowledge of biology found in academia with the expertise of MD Anderson's top clinicians. IACS has the singular goal of rapidly developing novel, effective and safe therapeutics that improve patient health. IACS executes programs with the highest probability of clinical success in a rigorous, goal-oriented, data-driven manner.
The Institute Assistant Scientist III participates in cross-functional research to identify and validate novel targets for neurodegenerative diseases, and translate these finding into novel therapeutic agents to benefit patients. An ideal candidate will have Master’s degree and three years’ experience working with rodent behavioral assays with chronic dosing, proven experience in experimental planning and data interpretation, and experience in histology techniques. Must be able to work in an interdisciplinary team to support our internal drug discovery efforts as well as to propose novel approaches to optimize and increase throughput of drug discovery projects.